Skip to main content

Table 1 Demographic data and baseline characteristics

From: A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder

  Groups Test of differences
  NAC Placebo  
Characteristics n/total % n/total % Chi-squarea
Gender—male 12/16 75.0 12/15 80.0 0.11
Race—White 16/16 100.0 14/15 93.3 1.01
Diagnosis
 Autistic disorder 7/16 43.8 7/15 46.7 0.03
 Asperger’s disorder 2/16 12.5 5/15 33.3 1.92
 PDD-NOS 7/15 43.8 3/15 20.0 1.98
CGI-S
 Marked (5) 6/16 37.5 9/15 60.0 1.57
 Severe (6) 9/16 56.3 6/15 40.0 0.82
 Extreme (7) 1/16 6.3 0/15 0.0 0.97
Concomitant medication (y/n) 6/16 37.5 10/15 66.7 2.64
Medication types
 Psychostimulants 3/16 18.7 3/15 20.0 0.01
 Alpha 2 agonists 1/16 6.2 2/15 13.3 0.44
 Antipsychotics 4/15 25.0 5/15 33.3 0.26
 Sleep aids 6/16 37.5 2/15 13.3 2.36
 Antidepressants 1/16 6.2 3/15 20.0 1.30
 Antiepileptic medication 2/16 12.5 0/15 0.0 2.01
  Mean SD Mean SD t testb
Age 7.63 2.5 8.20 2.9 0.59
Full scale IQ 86.27 21.8 87.43 11.7 0.18
Number of concomitant medications per participant 1.20 1.8 0.94 1.0 0.51
  1. aTwo-tailed significance + p < .10; *p < .05. No p values for these chi-squares reached significance at .05 and ranged from .11 to .87
  2. bTwo-tailed significance + p < .10; *p < .05 and ps ranged from .56 to .94
  3. NAC N-acetylcysteine, PDD-NOS pervasive developmental disorder not otherwise specified, CGI-S clinical global impression severity scale